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Abstract
Background: Phospholipase C epsilon 1 (PLCE1) (an effector of Ras) belonging to the phospholipase family plays
crucial roles in carcinogenesis and progression of several cancers, including squamous cell carcinoma of the head
and neck (SCCHN). A single nucleotide polymorphism (SNP, rs2274223) in PLCE1 has been identified as a novel
susceptibility locus in genome-wide association studies (GWAS) of esophageal squamous cell carcinoma (ESCC) and
gastric cardia adenocarcinoma (GCA) that share similar risk factors with SCCHN. Therefore, we investigated the
association between potentially functional SNPs in PLCE1 and susceptibility to SCCHN.
Methods: We genotyped three potentially functional SNPs (rs2274223A/G, rs3203713A/G and rs11599672T/G) of
PLCE1 in 1,098 SCCHN patients and 1,090 controls matched by age and sex in a non-Hispanic white population.
Results: Although none of three SNPs was alone significantly associated with overall risk of SCCHN, their
combined effects of risk alleles (rs2274223G, rs3203713G and rs11599672G) were found to be associated with risk
of SCCHN in a locus-dose effect manner (Ptrend = 0.046), particularly for non-oropharyngeal tumors (Ptrend = 0.017);
specifically, rs2274223 was associated with a significantly increased risk (AG vs. AA: adjusted OR = 1.29, 95% CI =
1.01-1.64; AG/GG vs. AA: adjusted OR = 1.30, 95% CI = 1.03-1.64), while rs11599672 was associated with a
significantly decreased risk (GG vs. TT: adjusted OR = 0.54, 95% CI = 0.34-0.86; TG/GG vs. TT: adjusted OR = 0.76,
95% CI = 0.61-0.95).
Conclusions: Our findings suggest that PLCE1 variants may have an effect on risk of SCCHN associated with
tobacco and alcohol exposure, particularly for those tumors arising at non-oropharyngeal sites. These findings,
although need to be validated by larger studies, are consistent with those in esophageal and gastric cancers.
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Background
Squamous cell carcinoma of the head and neck (SCCHN)
is the fifth most common cancer worldwide [1], which
includes malignancies at the sites of the oral cavity, lar-
ynx and pharynx. It was estimated that there were 48,010
new cases and 11,260 deaths of SCCHN in the United
States in 2010 [2]. Tobacco smoke and alcohol consump-
tion are the well-recognized risk factors for SCCHN, and
more recently human papillomavirus (HPV) is recognized
as a major risk factor for the oropharygeal cancer [3].
However, accumulative evidence also shows that genetic
factors, including family history and polymorphisms in
genes involved in multiple biological pathways, such as
carcinogen metabolism, DNA repair, cell cycle regulation,
apoptosis and other cellularp r o c e s s e s ,p l a yi m p o r t a n t
roles in the etiology of SCCHN [4,5]. Although an
increasing number of studies on genetic risk factors for
S C C H Nh a v eb e e np u b l i s h e d ,t h ee x a c tg e n e t i cb a s i so f
susceptibility to SCCHN is still not well defined.
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tion studies (GWASs) provided a more robust tool to find
novel susceptibility loci or genes for cancer susceptibility
by using high-throughput genotyping technology to inter-
rogate a large number of tagging polymorphisms in a high
density across the whole genome [6]. To date, more than
50 cancer GWASs have been published, including at least
15 different malignant tumors [7], which has greatly
improved our understanding of genetic basis of human
cancers. However, only one recent GWAS focused on
SCCHN risk and identified five variants at 4q21, 12q24
and ADH gene cluster, significantly associated with risk of
upper aerodigestive tract cancers (UATC) including
SCCHN [8]. It may be a very small proportion of SNPs
associated with SCCHN risk because of the strict criteria
for the GWAS significance level (P =1 0
-7 or P =1 0
-8).
Thus, further exploration for the genetic variants that did
not reach the GWAS significance level in the development
of SCCHN is needed.
In 2010, two large-scale genome-wide association stu-
dies [9,10] simultaneously reported that a new and notable
low-penetrance susceptibility locus (rs2274223) located in
the phospholipase C epsilon 1 gene (PLCE1) was strongly
associated with risk of esophageal squamous cell carci-
noma (ESCC) and gastric cardia adenocarcinoma (GCA)
in Chinese population. Rs2274223 is a non-synonymous
SNP located in exon 26 of the PLCE1 gene, causing the
amino acid change from histidine to arginine. Additionally,
one study also showed that the positive rates of the PLCE1
protein in ESCC and GCA tissues were significantly higher
than that in normal ones, suggesting a biologically plausi-
ble role of PLCE1 in carcinogenesis of human cancers [9].
The PLCE1 gene resides on chromosome 10q23 and
encodes phospholipase C epsilon 1 (PLCE1), which
belongs to the phospholipase family that catalyzes the
hydrolysis of polyphosphoinositides to generate secondary
messengers, such as inositol-1,4,5 trisphosphate and dia-
cylglycerol. Therefore, PLCE1 is involved in cell growth
and differentiation [11]. Studies have reported that PLCE1
f u n c t i o n sa sa ne f f e c t o ro fR a sa n dp l a y sc r u c i a lr o l e si n
carcinogenesis and progression of several cancers, includ-
ing cancers of the intestine [12], skin [13], bladder [14],
colorectal [15] and head and neck [16]. All these findings
further support the biological plausibility that genetic var-
iations, such as single nucleotide polymorphisms (SNPs)
in PLCE1 that affect the gene expression or protein func-
tions, may affect the risk of some cancers.
Studies have reported that SCCHN shares some similar
risk factors with ESCC and GCA, such as tobacco smoke
and alcohol consumption [17-19]. Thus, the exciting
results in the GWAS of ESCC and GCA, and the strong
biological evidence encouraged us to investigate the asso-
ciation between functional SNPs in PLCE1 and suscept-
ibility to SCCHN. In the present study, we performed
genotyping analyses of three potentially functional
SNPs in PLCE1 (rs2274223A/G, rs3203713A/G and
rs11599672T/G) in non-Hispanic whites and assessed
their associations with risk of SCCHN in our ongoing
hospital-based case-control study of 1,098 SCCHN cases
and 1,090 cancer-free controls matched to cases on age
(± 5 years) and sex.
Methods
Study populations
Participant recruitment has been described elsewhere
[20,21]. In brief, newly-diagnosed SCCHN cancer patients
were consecutively recruited from The University of Texas
M.D. Anderson Cancer Center between October 1999 and
October 2007. All cases were diagnosed with histologically
confirmed SCCHN, and there were no age, sex or stage
restrictions. Exclusion criteria included second SCCHN
primary tumors, primary tumors of the nasopharynx or
sinonasal tract, metastasized cancer from other organs, or
any histopathologic diagnosis other than SCCHN. Addi-
tionally, patients who had received prior surgery (other
than diagnostic biopsies), chemotherapy or radiation ther-
apy before recruitment, and any blood transfusion during
the preceding 6 months were also excluded.
Cancer-free controls were recruited from those visitors
in outpatient clinics at M.D. Anderson Cancer Center,
who were not genetically related to the patients or to each
other, and were frequency-matched to the cases on age
(±5 years), sex and ethnicity. The inclusion criterion for
controls was defined as the self-reported absence of prior
history of cancer. After the first survey using a short ques-
tionnaire to find out whether potential subjects were will-
ing to participate and qualified in this study, a written
informed consent was obtained, and a structured ques-
tionnaire was administered by trained interviewers to col-
lect demographic data and environmental exposure
history, such as age, sex, ethnicity, smoking and alcohol
consumption. After interview, approximately 30-ml
venous blood sample was collected from each participant.
The response rates for cases and controls were approxi-
mately 90% and 85%, respectively. In the analysis, a total
of 1,098 cases and 1,090 controls that completed the inter-
view and donated a one-time blood sample were included.
A l ls u b j e c t sw e r en o n - H i s p a n i cw h i t e s .T h i ss t u d yw a s
approved by the Institutional Review Board of M. D.
Anderson.
SNP Selection
Besides the non-synonymous SNP (rs2274223) identified
in the published GWAS, we also searched the NCBI
dbSNP database (http://www.ncbi.nlm.nih.gov/ build
131) for other common [minor allele frequency (MAF) ≥
0.05] and potentially functional SNPs located in the 5’
near gene, 5’-a n d3 ’-untranslated regions of PLCE1 by
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snpinfo.niehs.nih.gov/) [22]. In addition, the LD analyses
were performed to optimize SNP selection. We selected
additional two potentially functional SNPs in PLCE1:
rs3203713, located in the miRNA binding site (3’UTR)
and rs11599672, located in the transcription factor bind-
ing site (TFBS in 5’ near gene). Taken together, we
included three SNPs (rs2274223A/G, rs3203713A/G and
rs11599672T/G) in PLCE1 for the final genotyping.
Genotyping
We extracted genomic DNA from the buffy-coat fraction
of the blood samples using the Qiagen Blood DNA Mini
Kit (Qiagen Inc., Valencia, Calif) according to the manu-
facturer’s instruction and genotyped SNPs rs2274223 and
rs3203713 using the TaqMan allelic discrimination assay
on an ABI 7900 system (Applied Biosystems). Genotyping
was performed without knowing the subjects’ case or con-
trol status, and four negative controls (no DNA) and
duplicated commercial positive controls (TaqMan Control
Genomic DNA; Applied Biosystems) included in each
3 8 4 - w e l lp l a t ew e r eu s e df o rq u a l i t yc o n t r o l .T h ea c c o r -
dance achieved 100% for the duplicates of 5% of samples.
Polymerase chain reaction-restriction fragment length
polymorphisms (PCR-RFLP) method was also used to
identify genotypes of rs11599672, because the Taqman
assay was not applicable to this SNP. The antisense primer
was introduced a mismatched A to replace T at +2bp
from the polymorphic site to create an SspI restriction site
(sense: 5’- GGAGAGACATTCTGTTGGGTGA-3’;a n t i -
sense: 5’- CCTTCAAACCACCGCTGTAAT- 3’). A 155-
bp fragment containing this T/G site was amplified in the
PCR mixture consisted with approximately 20 ng of geno-
mic DNA, 2 pmol of each primer, 0.1 mM each dNTP, 1
× PCR buffer (50 mM KCl, 10 mM Tris HCl, and 0.1%
Triton X-100), 1.5 mM MgCl2, and 0.5 unit of Taq poly-
merase. The PCR profile consisted of an initial melting
step of 95°C for 5 min; 35 cycles of 95°C for 30 s, 59°C for
45 s, and 72°C for 1 min; and final extension step of 72°C
for 10 min. The PCR product was then digested with the
restriction enzyme SspI (New England BioLabs, Beverly,
MA) overnight at 37°C and separated on 3% agarose gel.
The T allele has the restriction site and produces two
bands of 134- and 21-bp, whereas the G allele lacks the
SspI restriction site, resulting in one band of 155-bp
(Figure 1). Finally, 10% of the samples were randomly
selected to perform the repeated assays, and the results
were 100% concordant. Direct sequencing was also con-
ducted to confirm the genotypes of rs11599672 (Figure 2).
Statistical analysis
We evaluated differences in selected demographic vari-
ables, risk factors, and frequencies of the PLCE1 geno-
types between cases and controls by using the c
2 test
and examined Hardy-Weinberg equilibrium by a good-
ness-of-fit c
2 test to compare the observed genotype fre-
quencies with the expected ones among the controls.
We estimated associations between PLCE1 variants and
SCCHN risk by computing odds ratios (ORs) and 95%
confidence intervals (CIs) from both univariate and mul-
tivariate logistic regression analyses with adjustment for
the known risk factors for SCCHN, such as age, sex,
smoking status and alcohol use. Haplotype frequencies
and individual haplotypes were generated by using SAS
PROC HAPLOTYPE based on the observed genotypes.
All statistical analyses were two sided, and P <0 . 0 5w a s
considered statistically significant. All the statistical ana-
lyses were performed with Statistical Analysis System
software (v.9.1 SAS Institute, Cary, NC).
Results
Characteristics of study subjects
The characteristics of cases and controls included in this
study are summarized in Table 1. The mean age was 57.1
years (±11.1) for cases and 56.6 years (±11.0) for controls.
There were no significant differences in the distributions
of age and sex between cases and controls (P = 0.676 and
0.581, respectively), suggesting the frequency-matching
on age and sex was adequate. However, 72.2% and 72.9%
of the SCCHN cases were smokers and drinkers, respec-
tively, which were significantly higher than that of the
controls (50.9% and 56.6%, respectively) (P< 0.001 for the
both). Of the 1,098 cases, 559 (50.9%) had tumors of the
oropharynx and 539 (49.1%) had tumors arising at non-
oropharynx sites including oral cavity, hypopharynx and
larynx. Furthermore, 272 cases (24.8%) presented with
Figure 1 PCR-based genotyping for rs11599672.
Figure 2 Direct sequencing results for the PLCE1 rs11599672 T
> G (TT, TG and GG).
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Page 3 of 9stage I-II and 826 cases (75.2%) presented with III-IV
stage.
Overall associations between PLCE1 variants and risk of
SCCHN
The genotype and allele distributions of three SNPs
(rs2274223, rs3203713 and rs11599672) in cases and con-
trols are shown in Table 2. The observed genotype fre-
quencies for these three polymorphisms were all in
Hardy-Weinberg equilibrium in the controls (P = 0.07,
0.98 and 0.72, respectively). The single locus analyses
revealed that genotype distributions of these three poly-
morphisms were not significantly different between over-
all cases and controls (P = 0.554 for rs2274223, P = 0.860
for rs3203713 and P = 0.265 for rs11599672, respec-
tively). However, we found that the frequencies of variant
rs2274223G and rs3203713G alleles (0.335 and 0.170,
respectively) among the cases were slightly higher than
those in the controls (0.320 and 0.162, respectively),
while the frequency of the variant rs11599672G allele
among the cases was slightly lower than that among the
controls (0.277 vs. 0.297), suggesting rs2274223G,
rs3203713G and rs11599672T alleles may be risk alleles
to be considered in further analyses.
The LD analysis showed that two PLCE1 polymorph-
isms rs2274223 and rs3203713 were in incomplete LD in
our study population (D’ =0 . 9 9 ,r
2 = 0.40), but these two
SNPs were not in LD with rs11599672. To estimate pos-
sible joint effects and potential locus-locus interactions
of PLCE1 polymorphisms on risk of SCCHN, we then
examined the combined effects of these three variants by
the number of putative risk alleles (i.e. rs2274223G,
rs3203713G and rs11599672T). As shown in Table 2, we
trichotomized the subjects into three groups with “0-1”,
“2-3” and “4-6” risk alleles. Compared with the group of
“0-1” risk allele, there was a locus-dose effect as the risk
allele number increased (Ptrend = 0.046). After adjustment
for age, sex, smoking and alcohol status, the group of “ 2-
3” risk alleles was borderline associated with risk of
SCCHN (adjusted OR = 1.20, 95% CI = 0.97-1.50,
adjusted P =0 . 0 9 6 )a n dt h e“4-6” risk allele group was
significantly associated with risk of SCCHN (adjusted OR
= 1.31, 95% CI = 1.00-1.73, adjusted P = 0.049). When
“2-3” and “4-6” groups were combined for a larger num-
ber in the same stratum, the association between a larger
number of risk alleles and risk of SCCHN remained
statistically significant (adjusted OR = 1.23, 95% CI =
1.00-1.52, adjusted P = 0.048).
Associations between PLCE1 variants and risk of SCCHN
by tumor sites
To investigate the modifying effects of PLCE1 variants on
risk of SCCHN with different tumor sites, we conducted
the stratification analysis by oropharyngeal and non-
oropharyngeal cancers. As shown in Table 2, rs2274223
variant genotypes were associated with a significantly
increased risk of SCCHN only for non-oropharyngeal sites
(AG vs. AA: adjusted OR = 1.29, 95% CI = 1.01-1.64,
adjusted P = 0.042; AG/GG vs. AA: adjusted OR = 1.30,
95% CI = 1.03-1.64; adjusted P = 0.025), while rs11599672
variant genotypes were associated with a significantly
decreased risk of SCCHN for this group of patients (GG
vs. TT: adjusted OR = 0.54, 95% CI = 0.34-0.86, adjusted
P = 0.009; TG/GG vs. TT: adjusted OR = 0.76, 95% CI =
0.61-0.95, adjusted P = 0.018). No association was
observed for rs3203713 variant genotypes and risk of
SCCHN in both subgroups. In addition, the locus-dose
effect of combined risk alleles was also seen in SCCHN
arising at non-oropharyngeal sites (Ptrend = 0.017). When
the group of “0-1” risk allele was used as the reference, the
group with “2-6” risk alleles had a significantly higher risk
of SCCHN arising at non- oropharyngeal sites (adjusted
OR = 1.35, 95% CI = 1.03-1.78; adjusted P = 0.033). How-
ever, these associations were not found for oropharyngeal
cancer.
Haplotype and stratification analyses
We further evaluated the combined effect of the three
polymorphisms on risk of SCCHN arising at non-orophar-
yngeal sites by using the haplotype analysis (Table 3). A
total of six haplotypes were derived from the observed
genotypes, of which Trs11599672Ars2274223Ars3203713 was the
most common haplotype in cases and controls with the
Table 1 Distribution of selected variables in SCCHN cases
and cancer-free controls
Variables Cases No. (%) Controls No. (%) P
a
All subjects 1,098 (100%) 1,090 (100%)
Age, yr 0.676
≤57 (median) 586 (53.4) 572 (52.5)
>57 (median) 512 (46.6) 518 (47.5)
Sex 0.581
Females 271 (24.7) 258 (23.7)
Males 827 (75.3) 832 (76.3)
Smoking status <0.001
Never 305 (27.8) 535 (49.1)
Ever 793 (72.2) 555 (50.9)
Alcohol status <0.001
Never 298 (27.1) 473 (43.4)
Ever 800 (72.9) 617 (56.6)
Tumor site
Oropharynx 559 (50.9)
Non-oropharynx 539 (49.1)
Stage
I-II 272 (24.8)
III-IV 826 (75.2)
a Two-sided c
2 test.
Ma et al. BMC Cancer 2011, 11:258
http://www.biomedcentral.com/1471-2407/11/258
Page 4 of 9frequencies of 53.6% and 53.0%, respectively. Compared
with the common haplotype, the G rs11599672A rs2274223A
rs3203713 haplotype was associated with a 28% decreased
risk of SCCHN arising at non- oropharyngeal sites
(adjusted OR = 0.72, 95% CI = 0.56-0.92); in contract, the
T rs11599672G rs2274223A rs3203713 haplotype was associated
with a 31% increased risk of SCCHN arising at non-oro-
pharyngeal sites (adjusted OR = 1.31, 95% CI = 1.00-1.72).
These associations were not observed for other haplotypes.
We then performed stratification analyses to evaluate
the effects of variant genotypes on risk of SCCHN aris-
ing at non-oropharyngeal sites by age, sex, smoking sta-
tus, alcohol use and disease stage (Table 4). The results
showed that the risk effect of rs2274223 was more evi-
dent in the younger (adjusted OR = 1.44, 95% CI =
1.02-2.02), male (adjusted OR = 1.51, 95% CI = 1.14-
2.00), smokers (adjusted OR = 1.33, 95% CI = 1.02-
1.72), drinkers (adjusted OR = 1.69, 95% CI = 1.25-2.28)
Table 2 Logistic regression analysis for associations between PLCE1 variant genotypes and SCCHN risk
Locus Genotype Controls (%) Overall (N = 1,098) Oropharynx (N = 559) Non-oropharynx (N = 539)
(N = 1,090) Cases (%) OR (95%CI)
a Cases (%) OR (95%CI)
a Cases (%) OR (95%CI)
a
PLCE1 rs2274223
AA 504 (46.3) 477 (43.5) 1.00 253 (45.3) 1.00 224 (41.6) 1.00
AG 474 (43.5) 506 (46.1) 1.14 (0.95-1.38) 248 (44.4) 1.09 (0.87-1.36) 258 (48.0) 1.29 (1.01-1.64)
GG 111 (10.2) 114 (10.4) 1.20 (0.88-1.62) 58 (10.3) 1.15 (0.80-1.64) 56 (10.4) 1.38 (0.93-2.06)
AG/GG 585 (53.7) 620 (56.5) 1.15 (0.97-1.38) 306 (54.7) 1.10 (0.89-1.36) 314 (58.4) 1.30 (1.03-1.64)
G allele 0.320 0.335
PLCE1 rs3203713
AA 759 (70.0) 753 (68.8) 1.00 391 (70.1) 1.00 362 (67.4) 1.00
AG 298 (27.5) 311 (28.4) 1.07 (0.88-1.31) 146 (26.2) 0.98 (0.77-1.25) 165 (30.7) 1.27 (0.99-1.64)
GG 27 (2.5) 31 (2.8) 1.28 (0.74-2.21) 21 (3.7) 1.74 (0.96-3.16) 10 (1.9) 0.80 (0.36-1.79)
AG/GG 325 (30.0) 342 (31.2) 1.09 (0.90-1.32) 167 (29.9) 1.04 (0.83-1.31) 175 (32.6) 1.23 (0.96-1.58)
G allele 0.162 0.170
PLCE1 rs11599672
TT 519 (48.3) 554 (50.8) 1.00 270 (48.8) 1.00 284 (52.9) 1.00
TG 473 (44.0) 469 (43.0) 0.94 (0.78-1.13) 246 (44.5) 1.03 (0.83-1.28) 223 (41.5) 0.81 (0.64-1.02)
GG 82 (7.7) 67 (6.2) 0.72 (0.50-1.03) 37 (6.7) 0.89 (0.58-1.37) 30 (5.6) 0.54 (0.34-0.86)
TG/GG 555 (51.7) 536 (49.2) 0.91 (0.76-1.08) 283 (51.2) 1.01 (0.82-1.25) 253 (47.1) 0.76 (0.61-0.95)
G allele 0.297 0.277
Combined effect of risk alleles
b
Trichotomy 0-1 263 (24.6) 235 (21.6) 1.00 124 (22.5) 1.00 111 (20.8) 1.00
2-3 607 (56.9) 630 (58.0) 1.20 (0.97-1.50) 320 (58.0) 1.14 (0.88-1.48) 310 (58.1) 1.29 (0.97-1.73)
4-6 197 (18.5) 221 (20.4) 1.31 (1.00-1.73) 108 (19.6) 1.23 (0.89-1.70) 113 (21.2) 1.54 (1.08-2.20)
P trend = 0.046 P trend = 0.210 P trend = 0.017
Dichotomy 0-1 263 (24.6) 235 (21.6) 1.00 124 (22.5) 1.00 111 (20.8) 1.00
2-6 804 (75.4) 851 (78.4) 1.23 (1.00-1.52) 428 (77.5) 1.16 (0.90-1.49) 423 (79.2) 1.35 (1.03-1.78)
a Adjusted for age, sex, smoking and alcohol status. The SNP calling rates were all >98% with 2 samples failed in rs2274223, 9 samples in rs3203713 and 24
samples in rs11599672.
b The risk alleles: rs2274223G, rs3203713G and rs11599672T.
Table 3 PLCE1 haplotype and risk of SCCHN arising at non-oropharyngeal sites
Haplotype frequencies
PLCE1 haplotypes
a Cases (N = 1,068) Controls (N = 2,134) Crude OR (95% CI) Adjusted OR
b (95% CI) P
b
N% N %
TAA 572 53.6 1131 53.0 1.00 1.00
GAA 128 12.0 318 14.9 0.80 (0.63-1.00) 0.72 (0.56-0.92) 0.008
TGA 119 11.1 198 9.3 1.19 (0.93-1.52) 1.31 (1.00-1.72) 0.049
GGG 87 8.1 179 8.4 0.96 (0.73-1.27) 0.96 (0.71-1.29) 0.771
TGG 96 9.0 170 8.0 1.12 (0.85-1.46) 1.10 (0.82-1.46) 0.528
GGA 66 6.2 138 6.5 0.95 (0.69-1.29) 0.85 (0.61-1.18) 0.334
a The alleles of haplotypes were arrayed as the location of the SNPs in PLCE1 stand from 5’ to 3’ (e.g. TAA denotes Trs11599672Ars2274223Ars3203713).
b Adjusted for age, gender, smoking and alcohol status in logistic models.
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Page 5 of 9Table 4 Stratification analysis for associations between PLCE1 variant genotypes and risk of SCCHN arising at non-oropharyngeal sites
Variables rs2274223 (cases/
controls)
Adjusted OR
a (95%CI) rs11599672 (cases/
controls)
Adjusted OR
a (95%CI) Combined effect of risk alleles
b (cases/
controls)
Adjusted OR
a (95%CI)
AA AG/GG TT TG/GG 0-1 2-6
Age, yr
≤57(median) 96/286 133/285 1.44 (1.02-2.02) 133/284 97/279 0.71 (0.50-1.00) 39/140 189/417 1.68 (1.09-2.59)
>57(median) 128/218 181/300 1.19 (0.87-1.63) 151/235 156/276 0.88 (0.64-1.20) 72/123 234/387 1.18 (0.82-1.70)
Gender
Females 84/119 100/139 0.97 (0.64-1.47) 96/110 89/145 0.73 (0.48-1.10) 44/74 140/177 1.30 (0.81-2.08)
Males 140/385 214/446 1.51 (1.14-2.00) 188/409 164/410 0.84 (0.64-1.10) 67/189 283/627 1.41 (1.00-1.98)
Smoking status
Never 46/236 57/298 0.99 (0.65-1.53) 54/266 48/261 0.85 (0.55-1.31) 27/116 74/407 0.81 (0.50-1.33)
Ever 178/268 257/287 1.33 (1.02-1.72) 230/253 205/294 0.73 (0.56-0.94) 84/147 349/397 1.65 (1.21-2.26)
Alcohol status
Never 79/210 76/262 0.84 (0.57-1.23) 86/223 69/244 0.67 (0.46-0.99) 34/112 120/352 1.33 (0.83-2.11)
Ever 145/294 238/323 1.69 (1.25-2.28) 198/296 184/311 0.86 (0.64-1.15) 77/151 303/452 1.42 (1.00-2.03)
Stage
I-II 87/504 137/585 1.40 (1.03-1.91) 114/519 111/555 0.84(0.62-1.14) 44/263 178/804 1.46 (1.01-2.13)
III-IV 137/504 177/585 1.24 (0.94-1.65) 170/519 142/555 0.78(0.59-1.03) 67/263 245/804 1.32 (0.94-1.85)
a Adjusted for age, sex, smoking and alcohol status (the stratified factor in each stratum excluded).
b The risk alleles: rs2274223G, rs3203713G and rs11599672T.
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9and subjects with early stage (adjusted OR = 1.40, 95%
CI = 1.03-1.91), whereas the protective effect of
rs11599672 was more prominent in the younger
(adjusted OR = 0.71, 95% CI = 0.50-1.00), smokers
(adjusted OR = 0.73, 95% CI = 0.56-0.94) and non-drin-
kers (adjusted OR = 0.67, 95% CI = 0.46-0.99). Addi-
tionally, the increased risk associated with the combined
effect of risk alleles was also more pronounced among
the younger (adjusted OR = 1.68, 95% CI = 1.09-2.59),
male (adjusted OR = 1.41, 95% CI = 1.00-1.98), smokers
(adjusted OR = 1.65, 95% CI = 1.21-2.26), drinkers
(adjusted OR = 1.42, 95% CI = 1.00-2.03) and subjects
with early-stage tumors (adjusted OR = 1.46, 95% CI =
1.01-2.13). However, no significant associations were
found for rs3203713 variant genotypes and risk of
SCCHN arising at non-oropharyngeal sites in every stra-
tum (data not shown). Heterogeneity test showed that
there was no significant heterogeneity (P >0 . 0 5 )i n
every two stratums except for that of rs2274223 strati-
fied by alcohol status (P =0 . 0 0 5 ) .I n t e r e s t i n g l y ,w e
detected a significant interaction between alcohol status
(never and ever) and rs2274223 variant genotypes
( A Aa n dA G / G G )f o rr i s ko fS C C H Na r i s i n ga tn o n -
oropharyngeal sites, even after the Bonferroni correction
(Pint = 0.004).
Discussion
In this case-control study, we investigated the associations
between three novel, potentially functional SNPs of PLCE1
(rs2274223, rs3203713 and rs11599672) and risk of
SCCHN in a non-Hispanic white population. Although we
did not find evidence of a main effect of each PLCE1 SNP
on overall SCCHN risk, the joint effect of these variants
appeared to contribute to risk of SCCHN in a dose-
response manner, especially for cancers arising at non-
oropharyngeal sites. Further, the subgroup analysis of
SCCHN arising at non-oropharyngeal sites showed that
variant genotypes of both rs2274223 and rs11599672 were
independently associated with the risk. These findings
suggested, for the first time, that potentially functional
polymorphisms of PLCE1 may play a role in the develop-
ment of SCCHN, particularly of those tumors at non-
oropharyngeal sites.
PLCE1 is known to be a direct downstream effector of
small GTPases (Ras, Rap1 and Rap2), with the presence
of two Ras-associating domains at its C terminus and a
CDC25 guanine exchange factor (CDC25 gef) domain at
its N terminus [11,23-25]. Since mutations in the RAS
gene family are associated with about 30% of all human
cancers, several studies have investigated the possible
role of PLCE1 in cancer development and progression
[13-16,26]. It has been reported that PLCE1 has an onco-
genic role in carcinogenesis of several human cancers,
including SCCHN, through distinct mechanisms, such as
inflammation, binding to the Ras family small GTPase,
and augmentation of angiogenesis [13-16,26]. Recent evi-
dence has demonstrated that PLCE1 mutations might
cause the nephritic syndrome [23] and diffuse mesangial
sclerosis (DMS) [27]; however, few studies have investi-
gated the association between genetic variants of PLCE1
and risk of human cancers.
Most recently, for the first time, Wang et al. found that
rs2274223, a nonsynonymous SNP of the PLCE1 gene,
was associated with an increased risk of ESCC and GCA
in a Chinese population by a two-stage GWAS in 9,053
ESCC cases, 2,766 GCA cases and 11,013 controls [8].
Likewise, in another GWAS including 2,115 ESCC cases,
2,240 gastric cancer cases and 3,302 controls in another
Chinese population, Abnet et al. also reported that
rs2274223 was a notable signal for susceptibility to ESCC
and GCA [10]. Despite the present study with 1,098
SCCHN cases and 1,090 controls may have a limited
power to detect weak associations between polymorph-
isms of PLCE1 including rs2274223 and overall risk of
SCCHN compared with the published GWA studies
[9,10], our results did show that subjects carrying more
risk alleles in PLCE1 (rs2274223G, rs3203713G and
rs11599672T) had a higher risk of SCCHN than those
with zero to one risk allele, especially for SCCHN arising
at non-oropharyngeal sites, suggesting a joint effect of
these SNPs on susceptibility to SCCHN. Given only a
modest effect of each SNP individually, evaluating their
combined effects may help us better understand any role
of PLCE1 SNPs in cancer etiology. Furthermore, different
carcinogenic mechanisms between esophageal and gastric
cardia cancers and SCCHN or genetic difference in differ-
ent populations may result in the discrepancy for the main
effect of rs2274223 between our study on SCCHN and
two GWASs of esophageal and gastric cancers.
Studies have shown that the oropharynx is the most
common site for HPV-associated SCCHN [28,29]; in con-
trast, SCCHN arising at non-oropharyngeal sites have
much lower HPV seroprevalence [28,30] and thus are
more likely to be caused by smoking and alcohol drinking,
similar to ESCC and GCA. In fact, 36% of our orophary-
geal cancer patients were never smokers compared to only
19% of patients with SCCHN arising at non-oropharygeal
sites. In our study, we found that rs2274223 and
rs11599672 had an independent effect on risk of smoking
and drinking related SCCHN arising at non-oropharyngeal
sites but not HPV-related oropharyngeal cancer. Even
after Bonferroni corrections, the association of rs11599672
with non-oropharyngeal SCCHN and association of
rs2274223 with drinking at non-orpharyngeal sites
remained significant, suggesting different roles of these
polymorphisms in the etiology of two different tumor sub-
sites. Additionally, subgroup analyses restricted to oro-
pharygeal cancer did find a similar pattern of risk (though
Ma et al. BMC Cancer 2011, 11:258
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Page 7 of 9non-significant) associated with variant genotypes of
rs2274223, rs11599672 and combined risk alleles among
smokers but not among never smokers (data not shown).
T h ef i n d i n g sf r o mG W A S sa n do u rs t u d yi m p l i e dt h a t
polymorphisms of PLCE1 are likely to be associated with
the development of human cancers related to tobacco and
alcohol exposure, which will need the validation from
large studies on different cancers.
Further, compared to the most common T rs11599672A
rs2274223A rs3203713 haplotype, both Trs11599672G rs2274223A
rs3203713 and G rs11599672A rs2274223A rs3203713 haplotypes
had a significant association with risk of SCCHN arising
at non-oropharyngeal sites, which further reflected the
main effect of rs2274223 G and rs11599672 G alleles on
risk of SCCHN arising at non-oropharyngeal sites. We
also found that the effects of rs2274223 and rs11599672
on risk of SCCHN arising at non-oropharyngeal sites
were segregated between the subgroups by smoking or
drinking status, indicating the possibility of gene-envir-
onment interactions. Indeed, we detected a significant
interaction between variant genotypes of rs2274223 and
alcohol status with a relatively small sample size, sup-
porting the role of a gene-environment interaction in
the development of SCCHN.
It has been identified that rs2274223 is a non-synon-
ymous SNP of PLCE1, and bioinformatics tools show
that rs3203713 in PLCE1 is located in the 3’UTR
(http://snpinfo.niehs.nih.gov/snpfunc.htm), which may
affect the binding of miRNA and target gene PLCE1.
Further, rs11599672 is located in the transcription factor
binding site (TFBS) of PLCE1 (http://snpinfo.niehs.nih.
gov/snpfunc.htm) and may result in the variation of
transcription activity and expression of PLCE1.C o n s i d -
ering the potentially functional significance of these
SNPs, it is biologically plausible that PLCE1 polymorph-
isms may contribute to the development of SCCHN.
However, we cannot exclude the possibility that the
findings from a subgroup analysis could be false positive
because of a limited sample size. More rigorous studies
with larger sample sizes, detailed HPV data and SNP
functional relevance are warranted to replicate our find-
ings and identify the underlying mechanism(s) of these
SNPs in the etiology of SCCHN.
Some limitations of this study need to be addressed.
Firstly, it is a hospital-based case-control study, and
inherent selection bias cannot be completely excluded.
However, the agreement of observed genotype distribu-
tions with Hardy-Weinberg equilibrium and similar
allele frequencies of our controls with those reported in
CEU populations from the dbSNP database (0.320 vs.
0.314 for rs2274223 G allele, 0.162 vs. 0.120 for
rs3203713 G allele, and 0.297 vs. 0.347 for rs11599672,
respectively) suggested that selection bias in terms of
genotype distribution would not be substantial, if any.
Secondly, it is uncertain whether the results from other
populations such as Chinese populations in the reported
GWASs [9,10] are generalizable to our study population;
yet similar findings from our non-Hispanic white sub-
jects further support a similar biological plausibility of
these SNPs. Thirdly, while we explored associations with
smoking and drinking expos u r e ,w ew e r en o ta b l et o
stratify our data by HPV exposure. Finally, 3 SNPs were
included in this study and we cannot rule out the possi-
bility of false-positive associations because of multiple
tests. Actually, only P values for the effect of rs11599672
variant genotypes on tumors arising at non-oropharyn-
geal sites and the association of rs2274223 variant geno-
types with drinking for non-oropharyngeal SCCHN risk
remained significant after Bonferroni corrections.
Conclusions
In summary, in this hospital-based case-control study,
we found that three PLCE1 SNPs may have a joint effect
on the risk of SCCHN, especially those arising at non-
oropharyngeal sites, including oral cavity, hypopharynx
or larynx, associated with smoking and alcohol expo-
sure. Furthermore, those results from subgroup analysis
suggest that variant genotypes of rs2274223 and
rs11599672 may independently affect the risk of
SCCHN arising at non-oropharyngeal sites. Additional
larger studies in different populations are needed to vali-
date our findings.
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